$224.41
0.470.21%
Last update: Oct 7, 4:42 PM
$224.41
0.470.21%
Alnylam Pharmaceuticals Inc
ALNYNASDAQ
Alnylam Pharmaceuticals (ALNY) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Alnylam Pharmaceuticals (ALNY) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided revenue in the range of $5.28B - $5.72B for the period.
Compared to prior guidance, Alnylam Pharmaceuticals maintained its revenue forecast from a prior range of $5.3B - $5.8B.
Alnylam Pharmaceuticals has issued 16 guidance updates between October 27, 2022 and July 30, 2026. During this period, the company raised its outlook 7 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $2.00 | $1.36 | $1.20 | $1.23 |
| Actual | $1.84 | $1.99 | $1.25 | $2.90 |
| Surprise | -8.00% | +46.3% | +4.17% | +135.8% |
| Revenue | ||||
| Estimate | $1.32B | $1.12B | $1.15B | $992.5M |
| Actual | $1.29B | $1.17B | $1.10B | $1.25B |
| Surprise | -2.02% | +4.26% | -4.64% | +25.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $2.18 | $2.55 | $2.01 | $2.49 |
| Revenue | ||||
| Consensus | $1.44B | $1.57B | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $1.84 | $2.00 | -8.00 % |
| Q1 | Apr 30, 2026 | $1.99 | $1.36 | 46.3 % |
| Q4 | Feb 12, 2026 | $1.25 | $1.20 | 4.17 % |
| Q3 | Oct 30, 2025 | $2.90 | $1.23 | 135.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $1.29B | $1.32B | -2.02 % |
| Q1 | Apr 30, 2026 | $1.17B | $1.12B | 4.26 % |
| Q4 | Feb 12, 2026 | $1.10B | $1.15B | -4.64 % |
| Q3 | Oct 30, 2025 | $1.25B | $992.47M | 25.9 % |
